Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Outset Medical, Inc. (NASDAQ: OM) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. Outset is a medical technology manufacturer focused on the Tablo Hemodialysis System, and its filings offer detail on financial performance, risk factors, and the business model behind its dialysis platform.
Among the key documents, investors can review Form 10-K annual reports and Form 10-Q quarterly reports, which typically include discussions of product revenue from Tablo consoles, recurring revenue from Tablo consumables and services, gross margin trends, operating expenses, and liquidity. These filings also reference the risks and uncertainties that could affect Outset’s results and the regulatory environment in which it operates.
Outset’s Form 8-K current reports are particularly relevant for tracking material events. For example, the company has filed 8-Ks to furnish press releases announcing second and third quarter financial results and updated or revised revenue guidance. Such filings summarize the nature of the event and incorporate the related press release by reference.
On this page, users can also monitor insider transaction reports on Form 4, proxy statements on Schedule 14A when available, and other submissions that shed light on governance, executive compensation, and ownership changes.
Stock Titan enhances these filings with AI-powered summaries that explain the main points of lengthy documents, highlight notable changes from prior periods, and surface items such as revenue mix, margin commentary, and forward-looking statements. Real-time updates from EDGAR help ensure that new OM filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 insider reports, are quickly reflected and summarized for easier review.
Outset Medical, Inc. insider ownership has been updated in an amended Form 3. The amendment reflects indirect holdings by BML Investment Partners, L.P., including short put options tied to 617,500 and 110,000 shares of Outset Medical and 1,902,201 shares of common stock. The filing states these derivative securities were previously omitted due to a clerical error.
Outset Medical, Inc. reported that its General Counsel, John L. Brottem, sold 2,842 shares of Common Stock at $3.35 per share in an open-market transaction. According to the footnote, this was a required “sell to cover” sale to satisfy tax withholding on 5,032 vesting RSU shares and was not a discretionary trade. Following the transaction, he directly owned 32,935 shares of Common Stock.
Outset Medical, Inc. Chair and CEO Leslie Trigg reported an open-market sale of 3,361 shares of Common Stock at
Outset Medical, Inc. executive vice president Marc Nash reported an open-market sale of 1,817 shares of common stock at
According to the disclosure, the shares were sold to cover tax withholding obligations arising from the vesting of 4,384 shares underlying restricted stock units granted on March 15, 2021, July 24, 2023, January 12, 2024 and June 10, 2025. The filing states this was a “sell to cover” transaction and not a discretionary trade by Nash.
OM filing: a Form 144 notice reports proposed sale related to the settlement of 9,319 vested restricted stock units on
John Brottem reported sales of Common Stock via a Form 144 notice. The filing lists three dispositions: 244 shares on
Outset Medical, Inc. received an amended Schedule 13G/A from Durable Capital Partners reporting that it no longer beneficially owns any of the company’s common stock. The filing shows 0 shares beneficially owned and a 0.0% ownership of the class, with no voting or dispositive power reported.
The reporting person confirms its holdings are below 5% of the class and states that any securities referenced were acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Outset Medical.
Outset Medical, Inc. drew an updated ownership disclosure from institutional investors led by Health Sciences, LP. A group of related investment entities, including Health Sciences, LP, Health Sciences GP, LLC, Healthcare Growth Equity I GP, LLC, Partner Asset Management, LLC and Brian D. Grossman, reports beneficial ownership of 530,796 shares of Outset Medical common stock. Based on 18,153,090 shares outstanding as of November 6, 2025, this stake represents about 2.9% of the company’s outstanding shares, keeping the group below the 5% large-holder threshold. The reporting parties state that the securities were not acquired and are not held to change or influence control of Outset Medical.
Outset Medical, Inc. reports a major shareholder’s existing stake. A 10% owner associated with BML Investment Partners, L.P. reports indirect beneficial ownership of 1,902,201 shares of Outset Medical common stock as of 02/12/2026. These shares are held by BML Investment Partners, L.P., whose general partner is BML Capital Management, LLC, managed by Mr. Leonard. He exercises investment and voting control over the fund’s shares but disclaims beneficial ownership except to the extent of his pecuniary interest.
BML Investment Partners, L.P. reported beneficial ownership of 1,902,201 shares of Outset Medical, Inc. common stock, representing 10.5% of the class as of the event dated 02/12/2026. All of these shares are held with shared voting and shared dispositive power; BML has no sole voting or sole dispositive power.
BML Investment Partners is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC, managed by Braden M. Leonard, who is deemed an indirect owner of the shares. The reporting persons certify the position is not held for the purpose of changing or influencing control of Outset Medical and disclaim being part of a statutory group.